Brokers Set Expectations for Johnson & Johnson’s Q3 2024 Earnings (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) – Equities research analysts at Zacks Research decreased their Q3 2024 earnings per share (EPS) estimates for shares of Johnson & Johnson in a note issued to investors on Thursday, September 26th. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $2.12 for the quarter, down from their previous forecast of $2.22. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.02 per share. Zacks Research also issued estimates for Johnson & Johnson’s Q4 2024 earnings at $2.33 EPS, FY2024 earnings at $9.98 EPS, Q3 2025 earnings at $2.59 EPS, Q4 2025 earnings at $2.63 EPS, FY2025 earnings at $10.58 EPS, Q1 2026 earnings at $2.76 EPS, Q2 2026 earnings at $2.82 EPS and FY2026 earnings at $11.27 EPS.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period last year, the company earned $2.80 EPS.

A number of other equities analysts also recently issued reports on JNJ. The Goldman Sachs Group cut their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. TD Cowen cut their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Finally, Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $161.40 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The stock has a 50-day moving average of $162.15 and a 200-day moving average of $154.16. The company has a market cap of $388.44 billion, a PE ratio of 10.06, a P/E/G ratio of 2.69 and a beta of 0.53. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.07%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Clifford Capital Partners LLC grew its stake in Johnson & Johnson by 53.5% in the 2nd quarter. Clifford Capital Partners LLC now owns 101,809 shares of the company’s stock valued at $14,880,000 after buying an additional 35,481 shares in the last quarter. University of Texas Texas AM Investment Management Co. grew its stake in Johnson & Johnson by 16.3% in the 2nd quarter. University of Texas Texas AM Investment Management Co. now owns 21,979 shares of the company’s stock valued at $3,212,000 after buying an additional 3,087 shares in the last quarter. Verity & Verity LLC grew its stake in Johnson & Johnson by 8.6% in the 2nd quarter. Verity & Verity LLC now owns 89,227 shares of the company’s stock valued at $13,041,000 after buying an additional 7,032 shares in the last quarter. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group grew its stake in Johnson & Johnson by 10.2% in the 2nd quarter. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group now owns 8,771 shares of the company’s stock valued at $1,282,000 after buying an additional 814 shares in the last quarter. Finally, Summit Wealth Partners LLC grew its stake in Johnson & Johnson by 0.6% in the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company’s stock valued at $1,463,000 after buying an additional 61 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.